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S U M M A R Y
Objectives: The objective of this study was to investigate the potential clinical roles of circulating soluble
interleukin (IL)-6 receptor (sIL-6R) and IL-6R expression on CD4+ T cells (CD4+ IL-6R+ T cells) in chronic
hepatitis B (CHB) patients.
Methods: One hundred and thirty-three subjects, including 72 CHB patients, 27 asymptomatic carriers,
eight acute hepatitis B (AHB) patients, and 26 healthy donors were included in this study. Plasma IL-6
and sIL-6R levels were measured by enzyme-linked immunosorbent assay (ELISA); the frequency of
CD4+ IL-6R+ T cells was detected by ﬂow cytometry analysis.
Results: Our data showed a signiﬁcant increase in plasma sIL-6R levels and the frequency of CD4+ IL-6R+
T cells in peripheral blood in CHB patients compared to asymptomatic carriers and healthy controls (both
p < 0.05). The elevated prevalence of CD4+ IL-6R+ T cells was positively associated with increased serum
alanine aminotransferase levels in CHB patients (r = 0.316, p = 0.007), but was not correlated with serum
hepatitis B virus (HBV) DNA load. Moreover, CHB patients with an HBV DNA load >1.0  106 copies/ml
had a lower level of plasma sIL-6R than those with an HBV DNA load <1.0  106 copies/ml.
Conclusions: Circulating sIL-6R and CD4+ IL-6R+ T cells were increased in CHB patients. Elevated plasma
sIL-6R is probably associated with HBV elimination, and CD4+ IL-6R+ T cells in peripheral blood might
contribute to the pathogenesis of liver injury in CHB patients.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Chronic hepatitis B virus (HBV) infection is a major public health
problem worldwide.1 Mounting evidence suggests that CD4 T cell
subset imbalance plays a key role in the pathogenesis of HBV-
associated liver diseases.2,3 Recently, interleukin (IL)-6 has been
demonstrated to play a pivotal role in directing CD4 T cell
differentiation and in shaping the immune response towards an
inﬂammatory phenotype.4–7 Moreover, several studies have shown
that the IL-6/IL-6 receptor (IL-6R) signaling pathway participates in
the cellular and humoral immune responses against HBV infection.
HighlevelsofserumIL-6havebeenfoundinchronichepatitisB (CHB)
patients8 and increased levels of serum soluble IL-6R (sIL-6R) have
beenmeasured in patients who responded to interferon-alpha (IFN-
a) therapy.9 The frequency of IL-6R expression on CD4 T cells (CD4+* Corresponding authors. Tel.: +86 755 25631087; fax: +86 755 25631087.
E-mail addresses: chenxinchun@gmail.com (X. Chen), zhoubp@hotmail.com
(B. Zhou).
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doi:10.1016/j.ijid.2010.12.008IL-6R+ T cells) in CHB patients has been found to be associated with
the proportion of Th17 cells, which are involved in the pathogenesis
ofHBV-associated liver injury.10,11 All this information indicates that
IL-6/IL-6R signaling may participate in the pathogenesis of HBV
infection; however the clinical signiﬁcanceof the IL-6/IL-6R complex
response in patients with CHB requires further evaluation.
IL-6 exerts its actions via its receptors: IL-6 binds to IL-6R
and subsequently activates a signal transducer molecule, gp130,
to mediate bioactivity.12,13 Almost all cells express membrane
gp130,14 whereas membrane-bound cognate receptor IL-6R
(CD126) is mainly conﬁned to hepatocytes and leukocytes; the
pathway through which IL-6 binds to cognate IL-6R is termed the
classical signaling pathway. In addition to cognate IL-6R, a soluble
formof the IL-6R (sIL-6R) has been identiﬁed in biological ﬂuids. sIL-
6R together with IL-6 can also stimulate cells that express only
gp130, a process referred to as trans-signaling.15 Thus, through the
trans-signaling pathway, the presence of sIL-6R widens the
spectrum of target cells of IL-6. Hence the physiological effector
of the IL-6/IL-6R signaling pathway correlates closely with
circulating sIL-6 levels and CD4+ IL-6R+ T cells.ses. Published by Elsevier Ltd. All rights reserved.
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of sIL-6R and CD4+ IL-6R+ T cells in HBV-infected patients of
different disease statuses, and also to evaluate the potential
association between the degree of liver injury and the levels of
circulating sIL-6R or the frequency of CD4+ IL-6R+ T cells in the
peripheral blood of CHB patients.
2. Methods
2.1. Patients and controls
Seventy-twopatientswithCHB,eightpatientswithacutehepatitis
B (AHB)atanearlystage,and27asymptomaticcarrierswereincluded
in this study. Diagnosis was in accordancewith previously described
criteria.16–19 Brieﬂy, CHBwasdeﬁned in the case of a subjectwhohad
been hepatitis B surface antigen (HBsAg)-positive for more than 6
months, with the presence of persistent or intermittent elevation of
alanine aminotransferase (ALT) levels and elevated HBV DNA levels
(>103 copies/ml, measured by a sensitive PCR assay), and with no
evidenceof livercirrhosisbasedonliverbiopsyorunequivocalclinical
andbiochemical data, or compatible ﬁndings on imaging techniques;
thesepatientshadbeenwithoutantiviral treatment forat least1year.
An asymptomatic carrierwas deﬁned as a casewhohadbeenHBsAg-
positive formore than 6months, with persistently normal ALT levels
on repeated measurements during a follow-up period of at least 1
year. AHB was deﬁned in the presence of highly elevated ALT values
(more than 10 times the upper limit of normal) and increased IgM
anti-hepatitis B core antibody (anti-HBc) values, in the absence of a
history of chronic HBV infection. Patients with other hepatitis virus
infections, HIV infection, or autoimmune, metabolic or drug-
associated liver diseases were excluded from the study. Twenty-six
healthy donors served as controls.
This study protocol was approved by the Ethics Committee of
Shenzhen Third People’s Hospital; written informed consent was
obtained from each study participant. The basic clinical character-
istics of patients and healthy donor controls are shown in Table 1.
2.2. Flow cytometry analysis
Fresh heparinized peripheral blood (100ml) was stained with
anti-CD3, anti-CD4, CD126 (membrane-bound IL-6R) monoclonal
antibodies (BD Biosciences, San Jose, CA, USA) at room temperature
for 20min. The blood was then lysed with lysing solution (BD
Pharmingen, USA), stained cells were acquired by FACSCalibur (BD
Biosciences), and data were analyzed by FACSDiva software (BD
Biosciences).
2.3. Quantiﬁcation of cytokines by ELISA
An enzyme-linked immunosorbent assay was used to quantify
IL-6 and sIL-6R following the manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA)Table 1
Clinical features of the populations enrolled
Healthy donors (n = 26) Asymptomatic carriers (n=27)
Sex, male/female 19/7 18/9
Age, years 25 (17–40) 34 (16–56)
ALT, U/l <40 21 (11–39)
TBIL, mmol/l <20 13 (6.9–20)
Log 10 HBV DNA ND 5.0 (2.7–8.0)
HBsAg, pos/neg 0/26 27/ 0
HBeAg, pos/neg 0/26 14/13
Anti-HBe, pos/neg 0/26 13/14
ALT, alanine aminotransferase; TBIL, total bilirubin; HBV, hepatitis B virus; HBsAg, hepatit
antigen; ND, not determined.
Data are expressed as median and range.2.4. Detection of serum ALT and HBV DNA levels
Serum creatinine and ALT were measured enzymatically
(Olympus AU640, Japan). Serum HBV DNA load was measured
by a quantitative PCR assay (PG Biotech, Shenzhen, China), with a
sensitivity of 5  102 copies/ml. Serum HBsAg, anti-HBc, hepatitis
B e antigen (HBeAg), antibody to hepatitis B e antigen (anti-HBe),
and antibody to hepatitis B surface antigen (anti-HBs) were
detected using commercially available microparticle immunoas-
says (AXSYM, Abbott Laboratories, Chicago, IL, USA).
2.5. Statistical analysis
Datawere analyzed using SPSS 11.5 software (SPSS Inc., Chicago,
IL, USA). Comparisons amongmultiple groupswere analyzed by the
one-way analysis of variance (ANOVA) Newman–Keuls multiple
comparison test. Comparisons between two groups were analyzed
by unpaired t-test. Correlation analysis was performed using the
Pearson’s t-test. All tests used were two-sided, and a p-value of
<0.05 was considered statistically signiﬁcant.
3. Results
3.1. Circulating sIL-6R levels and CD4+ IL-6R+ T cell frequencies are
increased in CHB patients
As demonstrated in previous studies, we found a signiﬁcantly
higher plasma IL-6 level in CHB patients than in healthy controls.
However we found no obvious differences with regard to elevated
IL-6 levels among asymptomatic carriers, CHB patients, and AHB
patients (Figure 1a).
Since the levels of IL-6 are not associated with liver injury in
HBV-infected subjects, we further investigated whether the levels
of sIL-6R and the frequency of CD4+ IL-6R+ T cells lead to liver
injury. Our results showed that sIL-6R plasma levels were
signiﬁcantly elevated in CHB patients compared with the other
patient groups, but were not obviously different among healthy
donors, asymptomatic carriers, and AHB patients (Figure 1b). By
analyzing the number of IL-6R-positive cells in CD3+ CD4+ T cells
(Figure 1d), we could determine the frequency of CD4+ IL-6R+ T
cells in patients of various disease statuses. The frequency of CD4+
IL-6R+ T cells was signiﬁcantly higher in CHB patients than in
asymptomatic carriers and healthy donors. AHB patients had a
higher percentage of CD4+ IL-6R+ T cells than CHB patients, while
there was no obvious difference between asymptomatic carriers
and healthy donors (Figure 1c).
3.2. Plasma sIL-6R levels and the frequency of CD4+ IL-6R+ T cells are
correlated with liver injury in CHB patients
Because of the differences in immune response between AHB
and CHB patients, in this study we only focused on determiningChronic hepatitis B patients (n=72) Acute hepatitis B patients (n=8)
55/17 6/2
34 (20–54) 26 (21–47)
231 (40–930) 774 (156–1597)
66 (6.5–632.5) 206 (15.4–517.8)
5.2 (2.7–8.4) 5.6 (3.4–7.1)
72/ 0 8/0
37/35 6/2
35/37 2/6
is B surface antigen; HBeAg, hepatitis B e antigen; anti-HBe, antibody to hepatitis B e
Figure 1. Levels of circulating sIL-6R and CD4+ IL-6R+ T cells in peripheral blood of HBV-infected subjects of different disease statuses. The concentrations of plasma IL-6 (a)
and sIL-6R (b), and the frequency of CD4+ IL-6R+ T cells (c), weremeasured in asymptomatic carriers (AsC), chronic hepatitis B patients (CHB), acute hepatitis B patients (AHB),
and healthy donors (HD). Differences among groups were analyzed using the one-way ANOVA Newman–Keuls multiple comparison test; **p < 0.01; ***p < 0.001; ns, not
signiﬁcant. (d) CD4+ IL-6R+ T cells were gated on the CD3+ CD4+ T cell subset, deﬁned by isotype control.
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IL-6R+ T cells are correlated with the severity of liver injury in CHB
patients. CHB patients were divided into different groups based on
their serum ALT level, HBV DNA load, and their HBeAg status,
separately. ALT cut-off levels of 120 U/l and >400 U/l were
applied according to the previously described diagnostic criteria.16
The cut-off value for HBV DNAwas 1.0  106 copies/ml, due to this
value being close to the median HBV DNA load value of the 72 CHB
patients enrolled in the study.
As shown inFigure 2, therewasno signiﬁcant difference in sIL-6R
levels in patientswithdifferent levels of ALT (Figure 2a) or byHBeAg
status (Figure 2c); however patients with serum HBV DNA loads
<1.0 106 copies/ml had higher levels of sIL-6R than patients with
serum HBV DNA loads >1.0  106 copies/ml (Figure 2b). Neverthe-
less there was no correlation between the level of sIL-6R and ALT
level (Figure 2d) or serum HBV DNA load (Figure 2e).
With regard to CD4+ IL-6R+ T cells in CHB patients, patients
with serumALT levels>400 IU/ml had a highermean percentage ofFigure 2. Association between the levels of plasma sIL-6R and liver injury in various chro
ALT level (a), HBV DNA load (b), and HBeAg status (c). Comparisons between groups w
represents one individual. The levels of plasma sIL-6R were not correlated with ALT level
analyzed using the Pearson’s t-test.circulating CD4+ IL-6R+ T cells than patients with serum ALT levels
<120 IU/ml and healthy donors (Figure 3a); Spearman analysis
showed a positive correlation between the frequency of CD4+ IL-
6R+ T cells and serum ALT levels (r = 0.316, p = 0.007) (Figure 3d).
On the other hand, there was no signiﬁcant difference in
circulating CD4+ IL-6R+ T cell frequency in patients with different
HBV DNA load levels (Figure 3b,e) or by HBeAg status (Figure 3c).
Because the level of sIL-6R and the frequency of CD4+ IL-6R+ T
cells participate in regulating the biological activity of IL-6, we
assumed that there would be associations between sIL-6R levels
and the frequency of CD4+ IL-6R+ T cells in CHB patients. However
we did not ﬁnd any correlation between them in this study
(Figure 4).
4. Discussion
Previous studies have suggested that IL-6 plays an important
role in patients with HBV infection, but data are scarce on thenic hepatitis B patients. Patients were divided into different groups based on serum
ere calculated using the unpaired t-test; ***p < 0.001; ns, not signiﬁcant. Each dot
s (d) or serum HBV DNA load (e) in chronic hepatitis B patients; the correlation was
Figure 3.Association between the frequency of CD4+ IL-6R+ T cells and liver injury in various chronic hepatitis B patients. Patientswere divided into different groups based on
serum ALT level (a), HBV DNA load (b), and HBeAg status (c). Comparisons between groups were calculated using the unpaired t-test; *p < 0.05; ***p < 0.001; ns, not
signiﬁcant. Each dot represents one individual. The frequency of CD4+ IL-6R+ T cells was positively correlated with ALT levels (r = 0.316, p = 0.007) (d), but not with HBV DNA
load in chronic hepatitis B patients (e); the correlation was analyzed using the Pearson’s t-test.
Figure 4. Association between plasma sIL-6R levels and the frequency of CD4+ IL-
6R+ T cells in chronic hepatitis B patients; the correlation was analyzed using the
Pearson’s t-test.
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patients. In this study, we analyzed the clinical signiﬁcance of sIL-
6R levels and CD4+ IL-6R+ T cells in CHB patients. Our results
showed that circulating sIL-6R levels in CHB patients were much
higher than in healthy donors, asymptomatic carriers, and AHB
patients, suggesting that sIL-6R levels may be correlated with
chronic liver injury. However, sIL-6R levels did not vary with ALT
levels and no correlation with the degree of injury in CHB patients
was found. Further analysis indicated that high sIL-6R levels were
found in CHB patients with low HBV DNA levels (<106 copies/ml).
Heinz et al. reported a signiﬁcant increase in plasma sIL-6R in CHB
patients who responded to IFN-a therapy with elimination of
serumHBV-DNA.20 Ho¨sel et al. demonstrated that IL-6 participates
in the early inhibition of HBV replication in hepatocytes.21
Furthermore, the abundant expression of gp130 molecules in
hepatoma cells has been shown;22 taken together, these results
indicate that high plasma sIL-6R in CHB patients may facilitate the
IL-6-mediated inhibition of HBV replication.
A signiﬁcantly higher frequency of CD4+ IL-6R+ T cells in the
peripheral blood of CHB patients compared with healthy donors
and asymptomatic carriers was shown in this study. Moreover, the
frequency of CD4+ IL-6R+ T cells in CHBwas found to be correlated
with the ALT level, but not with HBV DNA load or HBeAg status,
suggesting a close associationwith the degree of liver injury. As we
know, the frequency of CD4+ IL-6R+ T cells in peripheral blood isassociated with Th17 cell differentiation.23 Th17 cells are a subset
of pro-inﬂammatory CD4+ T cells and have been demonstrated to
mediate liver injury in HBV infection.16,18,24,25 IL-6/IL-6R on CD4+ T
cells may participate in liver injury by regulating Th17 cell
differentiation.
In summary, our results show an increased plasma sIL-6R in
CHB patients that might facilitate HBV elimination. CD4+ IL-6R+ T
cells in blood may contribute to the pathogenesis of liver injury in
CHB patients. However the cause of increased sIL-6R and CD4+ IL-
6R+ T cells in CHB still need to be further studied.
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